6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T Cells.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Vγ9Vδ2 T lymphocytes are the major human peripheral γδ T cell subset, with broad reactivity against stressed human cells, including tumor cells. Vγ9Vδ2 T cells are specifically activated by small phosphorylated metabolites called phosphoantigens (PAg). Stress-induced changes in target cell PAg levels are specifically detected by butyrophilin (BTN)3A1, using its intracellular B30.2 domain. This leads to the activation of Vγ9Vδ2 T cells. In this study, we show that changes in the juxtamembrane domain of BTN3A1, but not its transmembrane domain, induce a markedly enhanced or reduced γδ T cell reactivity. There is thus a specific requirement for BTN3A1's juxtamembrane domain for correct γδ T cell-related function. This work identified, as being of particular importance, a juxtamembrane domain region of BTN3A molecules identified as a possible dimerization interface and that is located close to the start of the B30.2 domain.

          Related collections

          Author and article information

          Journal
          J. Immunol.
          Journal of immunology (Baltimore, Md. : 1950)
          The American Association of Immunologists
          1550-6606
          0022-1767
          Jun 01 2017
          : 198
          : 11
          Affiliations
          [1 ] Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, CNRS, Université d'Angers, Université de Nantes, 44035 Nantes, France.
          [2 ] Labex-Immunotherapy Graft Oncology, Nantes 44000, France; and.
          [3 ] CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Immunité et Équipe Cancer, Aix-Marseille Université, 13284 Marseille, France.
          [4 ] Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, INSERM, CNRS, Université d'Angers, Université de Nantes, 44035 Nantes, France; Emmanuel.Scotet@inserm.fr.
          Article
          jimmunol.1601910
          10.4049/jimmunol.1601910
          28461569
          c51b820a-764e-4438-b8b7-b0cb87c16a6d
          History

          Comments

          Comment on this article